

Chapter 74

Vitiligo

Stanca A. Birlea, Richard A. Spritz,
& David A. Norris

REFERENCES

1. Howitz J et al: Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. *Arch Dermatol* **113**:47, 1977 [PMID: 9404690]
2. Boisseau-Garsaud AM et al: Familial aggregation of vitiligo in the French West Indies (Isle of Martinique). *Eur J Dermatol* **11**:554, 2001 [PMID:11701407]
3. Das SK et al: Studies on vitiligo. I. Epidemiological profile in Calcutta, India. *Genet Epidemiol* **2**:71, 1985 [PMID: 4054593]
4. Lu T et al: Vitiligo prevalence study in Shaanxi Province, China. *Int J Dermatol* **46**:47, 2007 [PMID: 17214719]
5. Hann S-K, Park YK, Chun WH: Clinical features of vitiligo. *Clin Dermatol* **15**:891, 1997 [PMID: 9404692]
6. Alkhateeb A et al: Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. *Pigment Cell Res* **16**:208, 2003 [PMID: 12753387]
7. Spritz RA: The genetics of generalized vitiligo. *Curr Dir Autoimmun* **10**:244, 2008 [PMID: 18460890]
8. Boissy RE, Spritz RA: Frontiers and controversies in the pathobiology of vitiligo: Separating the wheat from the chaff. *Exp Dermatol* **18**:583, 2009 [PMID: 19320739]
9. Gauthier Y, Cario Andre M, Taïeb A: A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? *Pigment Cell Res* **16**:322, 2003 [PMID: 12859615]
10. Orecchia GE: Neural pathogenesis. In: *Vitiligo*, edited by S-K Hann, JJ Nordlund. London, Blackwell Science, 2000, p. 142
11. Dell'Anna ML, Picardo M: A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. *Pigment Cell Res* **19**:406, 2006 [PMID: 16965269]
12. Lerner AB, Nordlund JJ: Vitiligo: The loss of pigment in skin, hair and eyes. *J Dermatol* **5**:1, 1978 [PMID: 353099]
13. Jin Y et al: Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. *New Engl J Med* **362**(18):1686-1697, 2010 [PMID: 20410501]
14. Happle R: Loss of heterozygosity in human skin. *J Am Acad Dermatol* **41**:143, 1999 [PMID: 10426882]
15. Taïeb A et al: Segmental vitiligo as the possible expression of cutaneous somatic mosaicism: Implications for common non-segmental vitiligo. *Pigment Cell Melanoma Res* **21**:646, 2008 [PMID: 18983534]
16. Ongenae K, Van Geel N, Naeyaert JM: Evidence for an autoimmune pathogenesis of vitiligo. *Pigment Cell Res* **16**:90, 2003 [PMID: 12622785]
17. Laberge G et al: Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. *Pigment Cell Res* **18**:300, 2005 [PMID: 16029422]
18. Kemp EH et al: Autoantibody response to melanocytes in the depigmenting skin disease vitiligo. *Autoimmun Rev* **6**:138, 2007 [PMID: 17289548]
19. Norris DA et al: Evidence for immunologic mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. *J Invest Dermatol* **90**:783, 1988 [PMID: 3373009]
20. Gilhar A et al: In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. *J Invest Dermatol* **105**:683, 1995 [PMID: 7594644]
21. Oyarbide-Valencia K et al: Therapeutic implications of autoimmune vitiligo T cells. *Autoimmune Rev* **5**:486, 2006 [PMID: 16920575]
22. Manga P et al: A role for tyrosinase related-protein 1 in 4-tert-butylphenol-induced toxicity in melanocytes. Implications for vitiligo. *Am J Pathol* **169**:1652, 2006 [PMID: 17071589]
23. Verheven J et al: Co-operation of IL-1 and IL-2 on T-cell activation in mononuclear cell cultures. *Immunol Invest* **30**:289, 2001 [PMID: 11777281]
24. Feliciani C, Gupta AK, Sauder DN: Keratinocytes and cytokine/growth factors. *Crit Rev Oral Biol Med* **7**:300, 1996 [PMID: 8986393]

25. Quaglino P et al: Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: Results from a single-institution hospital-based observational cohort study. *Ann Oncol* **21**:409, 2010 [PMID: 19622589]
26. Prignano F et al: Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. *J Dermatol Sci* **54**:157, 2009 [PMID: 19282153]
27. Dell'Anna ML et al: Membrane lipid defects are responsible for the generation of reactive oxygen species in peripheral blood mononuclear cells from vitiligo patients. *J Cell Physiol* **223**:187, 2010 [PMID: 20049874]
28. Hann S-K, Nordlund JJ: Clinical features of generalized vitiligo. In: *Vitiligo*, edited by S-K Hann, JJ Nordlund. London, Blackwell Science, 2000, p. 35
29. Koga M, Tango T: Clinical features and course of type A and type B vitiligo. *Br J Dermatol* **118**:223, 1988 [PMID: 3348967]
30. Song MS et al: Clinical study of vitiligo: comparative study of type A and type B vitiligo. *Ann Dermatol* **6**:22, 1994
31. el-Mofty AM, el-Mofty M: Vitiligo. A symptom complex. *Int J Dermatol* **19**:237, 1980 [PMID: 6993382]
32. Park KC, Youn JI, Lee YS: Clinical study of 326 cases of vitiligo. *Korean J Dermatol* **26**:200, 1988
33. Im S, Nordlund JJ: Physiological alterations in the depigmented skin of patients with vitiligo. In: *Vitiligo*, edited by S-K Hann, JJ Nordlund. London, Blackwell Science, 2000, p. 254
34. Moorthy RS, Inomata H, Rao NA: Vogt-Koyanagi-Harada syndrome. *Surv Ophthalmol* **39**:265, 1995 [PMID: 7725227]
35. Damico FM et al: New insights into Vogt-Koyanagi-Harada disease. *Arq Bras Oftalmol* **72**:413, 2009 [PMID: 19668980]
36. Okada T et al: Vitiligo in Vogt-Koyanagi-Harada disease: Immunohistological analysis of inflammatory site. *Graefes Arch Clin Exp Ophthalmol* **234**:359, 1996 [PMID: 8738701]
37. Alezzandrini AA: Unilateral manifestations of tapetoretinal degeneration, vitiligo, poliosis, grey hair, and hypoaacusia. *Ophthalmologica* **147**:409, 1964 [PMID: 14164681]
38. Guarnieri F, Aragona P, Vaccaro M: Vogt-Koyanagi-Harada syndrome. In: *Vitiligo: Problems and Solutions (Basic and Clinical Dermatology)*, edited by T Lotti, J Hercogov' a. New York, Marcel Dekker, 2004, p. 122
39. Bystryn J-C: Depigmentation other than vitiligo. In: *Vitiligo*, edited by S-K Hann, JJ Nordlund. London, Blackwell Science, 2000, p. 243
40. Taïeb A, Picardo M: VETF Members: The definition and assessment of vitiligo: A consensus report of the Vitiligo European Task Force. *Pigment Cell Res* **20**:27, 2007 [PMID: 17250545]
41. Le Poole IC et al: Presence or absence of melanocytes in vitiligo lesions: An immunohistochemical investigation. *J Invest Dermatol* **100**:816, 1993 [PMID: 7684427]
42. Kim YC et al: Histopathologic features in vitiligo. *Am J Dermatopathol* **30**:112, 2008 [PMID: 18360112]
43. Taïeb A, Picardo M: Clinical practice. Vitiligo. *N Engl J Med* **360**:160, 2009 [PMID: 19129529]
44. Sheth PB: Differential diagnosis of vitiligo vulgaris. In: *Vitiligo*, edited by S-K Hann, JJ Nordlund. London, Blackwell Science, 2000, p. 101
45. Birlea SA, Costin GE, Norris DA: New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. *Med Res Rev* **29**:514, 2009 [PMID: 19241402]
46. Koranne RV, Sachdeva KG: Vitiligo. *Int J Dermatol* **27**:676, 1988 [PMID: 3069756]
47. Bleeheh SS: Disorders of skin colour: Vitiligo. In: *Textbook of dermatology*, edited by RH Champion, JL Burton, DA Burns, SM Breathnach. Oxford, Blackwell Science, 1988, p. 1802
48. Ameen M, Exarchou V, Chu AC: Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. *Br J Dermatol* **145**:476, 2001 [PMID: 11531840]
49. Cui J, Shen LY, Wang GC: Role of hair follicles in the repigmentation of vitiligo. *J Invest Dermatol* **97**:410, 1991 [PMID: 1714927]
50. Arrunátegui A et al: Melanocyte reservoir in vitiligo. *Int J Dermatol* **33**: 484, 1994 [PMID: 7928031]
51. Horikawa T et al: Melanocyte mitogens induce both melanocyte chemokinesis and chemotaxis. *J Invest Dermatol* **104**:256, 1995 [PMID: 7530272]
52. Njoo MD et al: Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. *Arch Dermatol* **134**:1532, 1998 [PMID: 9875190]
53. Costin GE, Hearing VJ: Human skin pigmentation: Melanocytes modulate skin color in response to stress. *FASEB J* **21**:976, 2007 [PMID: 17242160]
54. Box NF, Terzian T: The role of p53 in pigmentation, tanning and melanoma. *Pigment Cell Melanoma Res* **21**:525, 2008 [PMID: 18761658]

55. Falabella R, Barona MI: Update on skin repigmentation therapies in vitiligo. *Pigment Cell Melanoma Res* 22:42, 2009 [PMID: 19040503]
56. Lotti T, Berti S, Moretti S: Vitiligo therapy *Expert Opin Pharmacother* 10:2779, 2009 [PMID: 19929701]
57. Westerhof W, Nieuweboer-Krobotova L: Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. *Arch Dermatol* 133:1525, 1997 [PMID: 9420536]
58. Njoo MD, Bos JD, Westerhof W: Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. *J Am Acad Dermatol* 42:245, 2000 [PMID:10642680]
59. Anbar TS et al: Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting body sites. *Photodermatol Photoimmunol Photomed* 22:157, 2006 [PMID: 16719871]
60. Nicolaidou E et al: Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. *J Am Acad Dermatol* 56:274, 2007 [PMID: 17224369]
61. Halder RM, Chappell JL: Vitiligo update. *Semin Cutan Med Surg* 28:86, 2009 [PMID: 19608058]
62. Parsad D et al: Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. *J Am Acad Dermatol* 50:63, 2004 [PMID: 14699367]
63. Bleehen SS: The treatment of vitiligo with topical corticosteroids. Light and electronmicroscopic studies. *Br J Dermatol* 94(Suppl. 12):43, 1976 [PMID: 773413]
64. Lawrence ID: Tacrolimus (FK 506): Experience in dermatology. *Dermatol Ther* 5:74, 1998
65. Kang HY, Choi YM Br J: FK 506 increases pigmentation and migration of human melanocytes. *Br J Dermatol* 155:1037, 2006 [PMID: 17034537]
66. Birlea SA, Costin GE, Norris DA: Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. *Curr Drug Targets* 9:345, 2008 [PMID: 18393827]
67. Schallreuter KU, Wood JM, Berger J: Low catalase levels in the epidermis of patients with vitiligo. *J Invest Dermatol* 97:1081, 1991 [PMID: 1748819]
68. Schallreuter K: State of the art on the treatment of vitiligo with pseudocatalase. *J Eur Acad Dermatol Venereol* 17(Suppl):30, 2003
69. Schallreuter KU et al: From basic research to the bedside: Efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo. *Int J Dermatol* 47:743, 2008 [PMID: 18613887]
70. Bakis-Petsoglou S, Le Guay J, Wittal R: A randomized, double blinded, placebo-controlled trial of pseudocatalase cream and narrow band UVB in the treatment of vitiligo. *Br J Dermatol* 161:910, 2009 [PMID: 19523170]
71. Patel DC, Evans AV, Hawk JL: Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: An open, single-centre study. *Clin Exp Dermatol* 27:641, 2002 [PMID: 12472535]
72. Gawkrödger DJ: Pseudocatalase and narrowband ultraviolet B for vitiligo: Clearing the picture. *Br J Dermatol* 161:721, 2009 [PMID: 19780755]
73. Passeron T, Ortonne JP: Use of the 308-nm excimer laser for psoriasis and vitiligo. *Clin Dermatol* 24:33, 2006 [PMID: 16427504]
74. Löntz W et al: Pigment cell transplantation for treatment of vitiligo: A progress report. *J Am Acad Dermatol* 30:591, 1994 [PMID: 8157785]
75. Gauthier Y: Techniques of melanocyte graft. *Ann Dermatol Venereol* 122:627, 1995 [PMID: 8745693]
76. Kahn AM et al: Vitiligo: Treatment by dermabrasion and epithelial sheet grafting—A preliminary report. *J Am Acad Dermatol* 28:773, 1993 [PMID: 8496424]
77. Kahn AM, Cohen MJ: Vitiligo: Treatment by dermabrasion and epithelial sheet grafting. *J Am Acad Dermatol* 33:646, 1995 [PMID: 7673499]
78. Laxmisha C, Thappa DM: Surgical pearl: Use of hypodermic needle to transfer minigrafts. *J Am Acad Dermatol* 54:707, 2006 [PMID: 16546595]
79. Malakar S, Lahiri K: Punch grafting for lip leucoderma. *Dermatology* 208:125, 2004 [PMID: 15057001]
80. Laxmisha C, Thappa DM: Surgical Pearl: Surgical tape for dressing of epidermal grafts in lip vitiligo. *J Am Acad Dermatol* 53:498, 2005 [PMID: 16112361]
81. van Geel N et al: Modified technique of autologous noncultured epidermal cell transplantation for repigmenting vitiligo: A pilot study. *Dermatol Surg* 27:873, 2001 [PMID: 1172254]
82. Gupta S, Goel A, Kanwar AJ: Surgical management of lip vitiligo. In: *Surgical Management of Vitiligo*, edited by BS Gupta, MJ Olsson, AJ Kanwar, JP Ortonne. Singapore, Blackwell Publishing, 2006, p. 747
83. Andreassi L et al: A new model of epidermal culture for the surgical treatment of vitiligo. *Int J Dermatol* 37:595, 1998 [PMID: 9732005]

84. Olsson MJ, Juhlin L: Transplantation of melanocytes in vitiligo. *Br J Dermatol* **132**:587, 1995 [PMID: 7748750]
85. Hariharan V et al: Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: Relevance to skin depigmentation. *J Invest Dermatol* **130**:211, 2010 [PMID: 19657355]
86. Nordlund JJ: Depigmentation for the treatment of extensive vitiligo, In: *Vitiligo*, edited by S-K Hann, JJ Nordlund. London, Blackwell Science, 2000, p. 207
87. Haxsel CL et al: A clinical trial and molecular study of photoadaptation in vitiligo. *Br J Dermatol* **160**:534, 2009 [PMID:19067714]